ctDNA, circulating tumor DNA; immunotherapy

*Among 69 patients with 198 samples without recurrences.
†Among 85 patients with 242 samples, 6 with recurrences.
‡Among patients with ER+ BC (8/8) all with distant recurrence.

Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.

Important Note: Guardant Reveal was developed as Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.